BPC May 18 updates – ARIA and DNAI Phase 2 data due at ASCO + updates for AFMD ARRY IMGN ORMP

May 18, 2016 No Comments by

Updates to the Company Pipeline Database for May 18, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary AFMD 3.10 AFM13 Hodgkin Lymphoma Phase 2 Phase 2a enrolment has slowed. Company to provide timeline update once enrolment trend is established ARIA 7.85 Brigatinib – ALTA trial Anaplastic lymphoma kinase positive (ALK+) […]

Daily News Read more

Pipeline updates from reporting companies – ARIA AVEO BCLI BDSI BLPH BSTC BTX CCXI CERU CYTX DERM FOMX GALE GTXI IMDZ MDGN OCUL OMER PBYI STEM TGTX TKAI VICL VKTX VTAE XENE ZIOP

May 11, 2016 No Comments by

Updates to the Company Pipeline Database for May 10, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ARIA 7.64 AP32788 Cancer – non-small cell lung cancer (NSCLC) Phase 1/2 Phase 1/2 enrolling as of May 2016 ARIA 7.64 Brigatinib – ALTA trial Anaplastic lymphoma kinase positive (ALK+) metastatic non-small cell […]

Daily News Read more

ARIA initiates Phase 3 Brigatinib trial. VKTX and BOTA updates. CRTV added to database.

Apr 11, 2016 No Comments by

Updates to the Company Pipeline Database for April 11, 2016 are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ARIA 6.34 Brigatinib ALK+ non-small cell lung cancer (NSCLC) – front line Phase 3 Phase 3 trial initiated April 2016. Enrolment to be completed 2018 BOTA 1.59 BTA585 Respiratory syncytial virus (RSV) […]

Daily News Read more

PTCT receives Refusal to File Letter. CLDX Phase 3 data due March + updates for ALDR AMAG ARIA BCRX ICPT INFI NVIV PRTK PTCT

Feb 24, 2016 No Comments

Updates to the Company Pipeline Database for February 23, 2016 are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ALDR 19.29 ALD403 Chronic Migraine Phase 2b Phase 2b data due 1Q 2016 ALDR 19.29 ALD403 – PROMISE 1 Frequent episodic migraine Phase 3 Phase 3 topline data due 1H 2017 AMAG […]

Read more

ALNY completes Phase 3 APOLLO enrollment + updates for ARIA CBYL DSCO REPH TENX TTHI

Feb 02, 2016 No Comments

Updates to the Company Pipeline Database for February 1, 2016 are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ALNY 69.75 Patisiran APOLLO Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR Phase 3 Phase 3 enrolment completed late January 2016. Data due 2017, with NDA to be filed late 2017 assuming […]

Read more

61 pipeline updates for 42 companies from May 7 and 8

May 09, 2015 1 Comment

Latest updates to the Company Pipeline Database for May 7 and 8, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ACHN 9.43 ACH-3422 in combination with ACH-3102 HCV Hepatitis C – treatment durations of 6, 8 and 12 weeks Phase 2 Phase 2 to be initiated 2Q 2015. SVR4 results are expected […]

Read more

Updates for week ending February 20

Feb 20, 2015 No Comments

Latest updates to the Company Pipeline Database for week ending February 20, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Link Text Updated AGIO 106.30 AG-348 Pyruvate kinase deficiency Phase 2 Phase 2 trial to be initiated 1H 2015 2/21/2015 ARIA 8.06 Brigatinib – ALTA trial Anaplastic lymphoma kinase […]

Read more

Latest pipeline updates. 40 in total!

Jan 13, 2015 No Comments

Latest updates to the Company Pipeline Database from January 12 and 13, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Text Updated ATRS 2.46 VIBEX QuickShot Testosterone deficiency Phase 3 Phase 3 initiated July 2014. Final patient dosed Nov 2015. Top-line pharmacokinetic data due 2Q 2015 1/14/2015 CPRX 2.87 […]

Read more

KBIO Phase 2 trial failure. CNAT data due this week + updates for ARIA CANF RARE TNXP TRVN AKBA BCLI CEMP CYTR MSTX RVNC RLYP GEVA

Jan 07, 2015 No Comments

Latest updates to the Company Pipeline Database from January 5 and 6, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Link Text Updated ARIA 6.51 Iclusig (ponatinib) Cancer – refractory chronic-phase chronic myeloid leukemia (CP-CML) Phase 2 Phase 2 dose ranging trial to be initiated mid 2015 1/7/2015 CANF […]

Read more

QRXPY Adcom date set. RMTI submits NDA. ARIA and CYTR initiate pivotal trials.

Mar 25, 2014 No Comments

QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced that the FDA has set 22 April 2014 as the date of the Advisory Committee meeting to consider the resubmitted Moxduo New Drug Application (NDA). The PDUFA date is 25 May, 2014. Rockwell Medical, Inc. (Nasdaq:RMTI)  announced the submission of a New Drug Application (NDA) to the FDA for Triferic (soluble […]

Read more

UTHR FDA Approval. BCRX files NDA. AUXL files sBLA. AMRN SPA decision due by Jan 15, PDUFA delayed + ARIA update

Dec 20, 2013 No Comments

United Therapeutics Corporation (NASDAQ: UTHR $87.84) announced today that the FDA has approved Orenitram (treprostinil) Extended-Release Tablets for the treatment of pulmonary arterial hypertension (PAH). BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX $6.92) announced that it has submitted a New Drug Application (NDA) for intravenous peramivir, for the treatment of acute uncomplicated influenza in adults. Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL $20.59)  announced […]

Read more